ATTENTION/WARNING - NE PAS DÉPOSER ICI/DO NOT SUBMIT HERE

Ceci est la version de TEST de DIAL.mem. Veuillez ne pas soumettre votre mémoire sur ce site mais bien à l'URL suivante: 'https://thesis.dial.uclouvain.be'.
This is the TEST version of DIAL.mem. Please use the following URL to submit your master thesis: 'https://thesis.dial.uclouvain.be'.
 

Efficacy of Exercise Therapy during treatments period (radio-, chemo- and/or immunotherapy) for lung cancer patients - A systematic review and meta-analysis

BURTON, Madeleine
(2021)

Files

Burton_Madeleine_32121200_2020-2021.pdf
  • UCLouvain restricted access
  • Adobe PDF
  • 1.2 MB

Details

Supervisors
Reychler, Gregory ; Caty, Gilles
Faculty
Faculté des sciences de la motricité
Degree label
Master [120] en sciences de la motricité, orientation générale, à finalité approfondie
Abstract
Lung cancer is the 3rd most frequent cancer and the leading cause of cancer-related death worldwide. Anti-cancer treatments involve side effects which add to the cancer related symptoms and can lead patient into a vicious circle of deconditioning associated with a decline in quality of life (QoL), worsening symptoms and side effects. However, physical activity level is a modifiable factor. Physical training may be a non-pharmacological solution to decrease cancer and treatment impacts. The primary aim of this SR and meta-analyse is to assess feasibility and safety of exercise therapy interventions during the time of treatment for lung cancer patients. Secondary aims are to evaluate the potential benefits on physical capacity, QoL, fatigue, dyspnea and other cancer-related and treatment-related symptoms, depression, anxiety and pulmonary function. We searched Pubmed, PEDro, Scopus and Sciencedirect. We included RCT’s, non-RCT’s and uncontrolled observational clinical trials, of lung cancer patients under treatment of radio-, chemo-, immunotherapy and/or targeted therapy who followed an exercise training program. We included 28 studies involving 1505 patients. Exercise Therapy is feasible and safe during the time of treatment for lung cancer patients. There are significant benefits for physical capacity, fatigue, anxiety and depression. No positive significant impacts were seen for the QoL, dyspnea, cancer- and treatment-related symptoms and pulmonary function.